An	O
antibody	O
directed	O
against	O
PDGF	O
receptor	O
beta	O
enhances	O
the	O
antitumor	B-Cancer
and	O
the	O
anti	O
-	O
angiogenic	O
activities	O
of	O
an	O
anti	O
-	O
VEGF	O
receptor	O
2	O
antibody	O
.	O

Platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
and	O
its	O
receptors	O
(	O
PDGFR	O
)	O
play	O
important	O
roles	O
in	O
tumorigenesis	O
through	O
stimulating	O
tumor	B-Cancer
growth	O
and	O
promoting	O
angiogenesis	O
via	O
enhancing	O
pericyte	B-Cell
recruitment	O
and	O
vessel	B-Multi-tissue_structure
maturation	O
.	O

Here	O
we	O
produced	O
a	O
neutralizing	O
antibody	O
,	O
1B3	O
,	O
directed	O
against	O
mouse	O
PDGFRbeta	O
.	O

1B3	O
binds	O
to	O
PDGFRbeta	O
with	O
high	O
affinity	O
(	O
9x10	O
(	O
-	O
11	O
)	O
M	O
)	O
and	O
blocks	O
PDGF	O
-	O
BB	O
from	O
binding	O
to	O
the	O
receptor	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
approximately	O
1	O
.	O
2	O
nM	O
.	O

The	O
antibody	O
also	O
blocks	O
ligand	O
-	O
stimulated	O
activation	O
of	O
PDGFRbeta	O
and	O
downstream	O
signaling	O
molecules	O
,	O
including	O
Akt	O
and	O
MAPK	O
p42	O
/	O
44	O
,	O
in	O
tumor	B-Cell
cells	I-Cell
.	O

In	O
animal	O
studies	O
,	O
1B3	O
significantly	O
enhanced	O
the	O
antitumor	B-Cancer
and	O
the	O
anti	O
-	O
angiogenic	O
activities	O
of	O
DC101	O
,	O
an	O
antibody	O
directed	O
against	O
mouse	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
,	O
in	O
a	O
pancreatic	B-Cancer
(	O
BxPC	B-Cancer
-	I-Cancer
3	I-Cancer
)	O
and	O
a	O
non	B-Cancer
-	I-Cancer
small	I-Cancer
cell	I-Cancer
lung	I-Cancer
(	I-Cancer
NCI	I-Cancer
-	I-Cancer
H460	I-Cancer
)	I-Cancer
tumor	I-Cancer
xenograft	I-Cancer
models	O
.	O

Treatment	O
with	O
the	O
combination	O
of	O
1B3	O
and	O
DC101	O
in	O
BxPC	B-Cancer
-	I-Cancer
3	I-Cancer
xenograft	I-Cancer
-	O
bearing	O
mice	O
resulted	O
in	O
tumor	B-Cancer
regression	O
in	O
58	O
%	O
of	O
mice	O
compared	O
to	O
that	O
in	O
18	O
%	O
of	O
mice	O
treated	O
with	O
DC101	O
alone	O
.	O

Taken	O
together	O
,	O
these	O
results	O
lend	O
great	O
support	O
to	O
use	O
PDGFRbeta	O
antagonists	O
in	O
combinations	O
with	O
other	O
antitumor	B-Cancer
and	O
/	O
or	O
anti	O
-	O
angiogenic	O
agents	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
cancers	B-Cancer
.	O

